Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate in Pulmonary Arterial Hypertension
NCT06872112Phase 1Recruiting
- Start
- Apr 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of artesunate in pulmonary arterial hypertension (PAH). Primary endpoint: Number of Participants with treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) at 16 weeks. Started Apr 2026; status: recruiting.
02
Drugs
artesunate
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06872112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06872112.